Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention

References

• Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012;120(6):1165-74
   PubMed Web of Science ®Google Scholar
• Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol 2012;30(14):1663-9
   PubMed Web of Science ®Google Scholar
• Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115(16):3206-14
   PubMed Web of Science ®Google Scholar
• Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011;118(8):2077-84
   PubMed Web of Science ®Google Scholar
• Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010;28(14):2339-47
   PubMed Web of Science ®Google Scholar
• Rivera GK, Zhou Y, Hancock ML, et al. Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer 2005;103(2):368-76
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 2000;14(5):783-5
   PubMed Web of Science ®Google Scholar
• Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010;24(3):521-35
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999;94(7):2225-9
   PubMed Web of Science ®Google Scholar
• Choi S, Henderson MJ, Kwan E, et al. Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone. Blood 2007;110(2):632-639s
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Pui CH. Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 2013;14(6):e205-17
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008;322(5906):1377-80
   PubMed Web of Science ®Google Scholar
• Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2006;108(2):711-17
   PubMed Web of Science ®Google Scholar
• Szczepanski T, van der Velden VH, Waanders E, et al. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol 2011;29(12):1643-9
   PubMed Web of Science ®Google Scholar
• Konrad M, Metzler M, Panzer S, et al. Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone. Blood 2003;101(9):3635-40
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998;339(9):605-15
   PubMed Web of Science ®Google Scholar
• Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000;96(1):24-33
   PubMed Web of Science ®Google Scholar
• Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370(9583):240-50
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Vitale A, Cazzaniga G, et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica 2013;98(11):1702-10
   PubMed Web of Science ®Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112(5):1646-54
   PubMed Web of Science ®Google Scholar
• Ribera JM, Ribera J, Genesca E. Treatment of adolescent and young adults with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 2014;6(1):e2014052
   Google Scholar
• Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14(1):18-24
   PubMed Web of Science ®Google Scholar
• Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Haematol 2002;15(4):695-711
   PubMed Web of Science ®Google Scholar
• Mullighan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Clin Cancer Res 2011;17(3):396-400
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10(2):147-56
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012;481(7380):157-63
   PubMed Web of Science ®Google Scholar
• Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2014;166(3):421-4
   PubMed Web of Science ®Google Scholar
• Uckun FM, Sather HN, Gaynon PS, et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 1997;90(1):28-35
   PubMed Web of Science ®Google Scholar
• Putti MC, Rondelli R, Cocito MG, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998;92(3):795-801
   PubMed Web of Science ®Google Scholar
• Pui CH, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991;78(5):1327-37
   PubMed Web of Science ®Google Scholar
• Lilleyman JS, Hann IM, Stevens RF, et al. Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. United Kingdom Medical Research Council’s Working Party on Childhood Leukaemia. Br J Haematol 1992;81(1):52-7
   PubMed Web of Science ®Google Scholar
• Hann I, Vora A, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Br J Haematol 2001;113(1):103-14
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Moorman AV, Broadfield ZJ, et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004;125(5):552-9
   PubMed Web of Science ®Google Scholar
• Heerema NA, Nachman JB, Sather HN, et al. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children’s cancer group. Blood 1999;94(12):4036-45
   PubMed Web of Science ®Google Scholar
• Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007;110(4):1112-15
   PubMed Web of Science ®Google Scholar
• Pui CH, Carroll AJ, Raimondi SC, et al. Clinical presentation, karyotypic characterization, and treatment outcome of childhood acute lymphoblastic leukemia with a near-haploid or hypodiploid less than 45 line. Blood 1990;75(5):1170-7
   PubMed Web of Science ®Google Scholar
• Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45(3):242-52
   PubMed Web of Science ®Google Scholar
• Raimondi SC, Zhou Y, Mathew S, et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 2003;98(12):2715-22
   PubMed Web of Science ®Google Scholar
• Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood 2003;102(8):2756-62
   PubMed Web of Science ®Google Scholar
• Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol 2000;18(9):1876-87
   PubMed Web of Science ®Google Scholar
• Sutcliffe MJ, Shuster JJ, Sather HN, et al. High concordance from independent studies by the Children’s Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children’s Oncology Group (COG) initiative. Leukemia 2005;19(5):734-40
   PubMed Web of Science ®Google Scholar
• Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol 2004;83(Suppl 1):S121-3
   PubMedGoogle Scholar
• Paulsson K, Forestier E, Andersen MK, et al. High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL. 1992/2000 protocols. Haematologica 2013;98(9):1424-32
   PubMed Web of Science ®Google Scholar
• Kaspers GJ, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995;85(3):751-6
   PubMed Web of Science ®Google Scholar
• Synold TW, Relling MV, Boyett JM, et al. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994;94(5):1996-2001
   PubMed Web of Science ®Google Scholar
• Romana SP, Mauchauffe M, Le Coniat M, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995;85(12):3662-70
   PubMed Web of Science ®Google Scholar
• Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011;29(5):551-65
   PubMed Web of Science ®Google Scholar
• Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995;9(12):1985-9
   PubMed Web of Science ®Google Scholar
• Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood 1997;90(2):571-7
   PubMed Web of Science ®Google Scholar
• Loh ML, Goldwasser MA, Silverman LB, et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006;107(11):4508-13
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Wichlan D, Devidas M, et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study. J Clin Oncol 2008;26(13):2186-91
   PubMed Web of Science ®Google Scholar
• Jeha S, Pei D, Raimondi SC, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009;23(8):1406-9
   PubMed Web of Science ®Google Scholar
• Garg R, Kantarjian H, Thomas D, et al. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer 2009;115(10):2147-54
   PubMed Web of Science ®Google Scholar
• Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013;27(11):2165-76
   PubMed Web of Science ®Google Scholar
• Conter V, Valsecchi MG, Parasole R, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood 2014
   PubMed Web of Science ®Google Scholar
• Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000;342(14):998-1006
   PubMed Web of Science ®Google Scholar
• Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 2009;27(31):5175-81
   PubMed Web of Science ®Google Scholar
• Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0031. Leukemia 2014;28(7):1467-71
   PubMed Web of Science ®Google Scholar
• Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012;13(9):936-45
   PubMed Web of Science ®Google Scholar
• Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nature reviews. Drug Dis 2007;6(2):149-65
   Google Scholar
• Harrison CJ, Moorman AV, Schwab C, et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 2014;28(5):1015-21
   PubMed Web of Science ®Google Scholar
• Izraeli S. Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside? Br J Haematol 2010;151(2):119-31
   PubMed Web of Science ®Google Scholar
• Palmi C, Vendramini E, Silvestri D, et al. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia 2012;26(10):2245-53
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453(7191):110-14
   PubMed Web of Science ®Google Scholar
• van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014;123(11):1691-8
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009;360(5):470-80
   PubMed Web of Science ®Google Scholar
• Dorge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013;98(3):428-32
   PubMed Web of Science ®Google Scholar
• Palmi C, Valsecchi MG, Longinotti G, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? Haematologica 2013;98(8):1226-31
   PubMed Web of Science ®Google Scholar
• Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010;24(7):1258-64
   PubMed Web of Science ®Google Scholar
• van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013;122(15):2622-9
   PubMed Web of Science ®Google Scholar
• Palmi C, Lana T, Silvestri D, et al. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to “incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia”. Haematologica 2013;98(12):e164-5
   PubMed Web of Science ®Google Scholar
• Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010;116(23):4874-84
   PubMed Web of Science ®Google Scholar
• Clappier E, Auclerc MF, Rapion J, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 2014;28(1):70-7
   PubMed Web of Science ®Google Scholar
• Zaliova M, Zimmermannova O, Dorge P, et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia 2014;28(1):182-5
   PubMed Web of Science ®Google Scholar
• Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009;10(2):125-34
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011;471(7337):235-9
   PubMed Web of Science ®Google Scholar
• De Kronnie G, Silvestri D, Vendramini E, et al. Philadelphia-like signature in childhood acute lymphoblastic leukemia: the AIEOP experience. Blood 2013;122:353
   Web of Science ®Google Scholar
• Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012;22(2):153-66
   PubMed Web of Science ®Google Scholar
• Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 2013;31(25):e413-16
   PubMed Web of Science ®Google Scholar
• Lengline E, Beldjord K, Dombret H, et al. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 2013;98(11):e146-8
   PubMed Web of Science ®Google Scholar
• Inokuchi K, Wakita S, Hirakawa T, et al. RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations. Int J Hematol 2011;94(3):255-60
   PubMed Web of Science ®Google Scholar
• Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 2014. [Epub ahead of print]
   Google Scholar
• Meyer JA, Wang J, Hogan LE, et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013;45(3):290-4
   PubMed Web of Science ®Google Scholar
• Tzoneva G, Perez-Garcia A, Carpenter Z, et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nature Med 2013;19(3):368-71
   PubMed Web of Science ®Google Scholar
• Meijerink JP. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2010;23(3):307-18
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 2012;122(10):3398-406
   PubMed Web of Science ®Google Scholar
• Paganin M, Ferrando A. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev 2011;25(2):83-90
   PubMed Web of Science ®Google Scholar
• Yang JJ, Cheng C, Devidas M, et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012;120(20):4197-204
   PubMed Web of Science ®Google Scholar
• Yang JJ, Cheng C, Yang W, et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009;301(4):393-403
   PubMed Web of Science ®Google Scholar
• Rousseau J, Gagne V, Labuda M, et al. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 2011;118(22):5883-90
   PubMed Web of Science ®Google Scholar
• Ben Tanfous M, Sharif-Askari B, Ceppi F, et al. Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5(7):819-34
   PubMed Web of Science ®Google Scholar
• Sepe DM, McWilliams T, Chen J, et al. Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer 2012;58(5):695-700
   PubMed Web of Science ®Google Scholar
• Aplenc R, Thompson J, Han P, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005;65(6):2482-7
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004;4(1):66-72
   PubMed Web of Science ®Google Scholar
• Salazar J, Altes A, del Rio E, et al. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J 2012;12(5):379-85
   PubMed Web of Science ®Google Scholar
• El-Khodary NM, El-Haggar SM, Eid MA, Ebeid EN. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2012;29(3):2053-62
   PubMed Web of Science ®Google Scholar
• Hogan LE, Meyer JA, Yang J, et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 2011;118(19):5218-26
   PubMed Web of Science ®Google Scholar
• Marshall GM, Dalla Pozza L, Sutton R, et al. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation. Leukemia 2013;27(7):1497-503
   PubMed Web of Science ®Google Scholar
• Gaynon PS, Bleyer WA, Steinherz PG, et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990;18(4):273-9
   PubMedGoogle Scholar
• Lauten M, Moricke A, Beier R, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica 2012;97(7):1048-56
   PubMed Web of Science ®Google Scholar
• Janka-Schaub GE, Stuhrk H, Kortum B, et al. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group]. Klinische Padiatrie 1991;203(4):231-5
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Young ML, et al. Induction failure in acute lymphoblastic leukemia of childhood. Cancer 1999;85(6):1395-404
   PubMed Web of Science ®Google Scholar
• Oudot C, Auclerc MF, Levy V, et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008;26(9):1496-503
   PubMed Web of Science ®Google Scholar
• Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 2012;366(15):1371-81
   PubMed Web of Science ®Google Scholar
• Cave H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer–Childhood Leukemia Cooperative Group. N Engl J Med 1998;339(9):591-8
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351(9102):550-4
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352(9142):1731-8
   PubMed Web of Science ®Google Scholar
• Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:7-12
   PubMed Web of Science ®Google Scholar
• Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23(5):1083-98
   PubMed Web of Science ®Google Scholar
• Campana D. Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 2012;19(4):313-18
   PubMed Web of Science ®Google Scholar
• Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115(23):4657-63
   PubMed Web of Science ®Google Scholar
• Wu D, Sherwood A, Fromm JR, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012;4(134):134ra163
   Web of Science ®Google Scholar
• Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120(26):5173-80
   PubMed Web of Science ®Google Scholar
• Available from: www.euroclonality.org/EuroClonality-NGS.pdf
   Google Scholar
• Available from: www.eslho.org
   Google Scholar
• Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study. Leukemia 2003;17(8):1566-72
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 2008;111(12):5477-85
   PubMed Web of Science ®Google Scholar
• Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009;27(31):5168-74
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100(1):52-8
   PubMed Web of Science ®Google Scholar
• Coate L, Cuffe S, Horgan A, et al. Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010;28(26):4029-37
   PubMed Web of Science ®Google Scholar
• Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet 2013;58(6):346-52
   PubMed Web of Science ®Google Scholar
• Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther 2014;95(3):269-80
   PubMed Web of Science ®Google Scholar
• Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013;93(4):324-5
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009;113(24):6077-84
   PubMed Web of Science ®Google Scholar
• Paugh SW, Stocco G, Evans WE. Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr 2010;22(6):703-10
   PubMed Web of Science ®Google Scholar
• Dulucq S, Laverdiere C, Sinnett D, Krajinovic M. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies. Expert Opin Drug Metab Toxicol 2014;10(5):699-719
   PubMed Web of Science ®Google Scholar
• Malbasa T, Kodish E, Santacroce SJ. Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs 2007;24(3):139-51
   PubMed Web of Science ®Google Scholar
• Spinetta JJ, Masera G, Eden T, et al. Refusal, non-compliance, and abandonment of treatment in children and adolescents with cancer: a report of the SIOP Working Committee on Phychosocial Issues in Pediatric Oncology. Med Pediatr Oncol 2002;38(2):114-17
   PubMedGoogle Scholar
• Bhatia S, Landier W, Hageman L, et al. Adherence to oral 6-mercaptopurine in African American and Asian children with acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2014;124(15):2345-53
   PubMed Web of Science ®Google Scholar
• Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood 2007;109:926-35
   PubMed Web of Science ®Google Scholar
• Moorman AV, Richards SM, Robinson HM, et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 2007;109:2327-30
   PubMed Web of Science ®Google Scholar